+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07213960

Sequential Phase 23 Study Evaluating Twice-Weekly Subcutaneous APL2 in Adults and Adolescents with Focal Segmental Glomerulosclerosis

Led by Apellis Pharmaceuticals, Inc. · Updated on 2026-09-02

270

Participants Needed

2

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of APL2, a complement C3 inhibitor, in patients diagnosed with Focal Segmental Glomerulosclerosis FSGS. This sequential phase 23 study includes an initial open-label phase 2 study in adults followed by a randomized, placebo-controlled, double-blind phase 3 study involving adults and adolescents. The study aims to assess the impact of APL2 on proteinuria and kidney function in this patient population. Participants receive subcutaneous infusions of APL2 twice weekly. In phase 2, adults receive 1080 mg per infusion. In phase 3, dosing varies for adolescents based on weight, with specific dose adjustments for those weighing 30 to less than 50 kg. The placebo group receives sterile infusions matching the active treatment volume. Phase 2 focuses on safety and efficacy over 12 weeks, while phase 3 extends evaluation to 52 weeks with additional follow-up to 104 weeks for longer-term outcomes. During the study, participants undergo regular assessments including measurements of urine protein to creatinine ratio uPCR, urine albumin to creatinine ratio uACR, and estimated glomerular filtration rate eGFR. These tests help monitor kidney function and response to treatment. Safety and efficacy data are collected throughout the treatment and follow-up periods, with the primary outcomes focused on changes in proteinuria from baseline to 12 weeks in phase 2 and 52 weeks in phase 3. The total study duration extends until December 2029.

CONDITIONS

Brief Title

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

Research Team

A

Apellis Clinical Trial Information Line

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here